EBITDA Margin % is calculated as EBITDA divided by its Revenue. AbCellera Biologics's EBITDA for the
three
months ended in Mar. 2026 was $-44.53 Mil. AbCellera Biologics's Revenue for the
three
months ended in Mar. 2026 was $8.32 Mil. Therefore, AbCellera Biologics's EBITDA margin for the quarter that ended in Mar. 2026 was -535.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AbCellera Biologics EBITDA Margin % Related Terms
AbCellera Biologics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs SRPT, RAPP, RXRX: EBITDA Margin % Comparison
For the Biotechnology subindustry, AbCellera Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a EBITDA Margin % of -535.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #587 out of 944 companies in the Biotechnology industry, placing it in the top 62.2%.
Is AbCellera Biologics' EBITDA Margin % too high?
AbCellera Biologics' current EBITDA Margin % is -535.48%. Based on the distribution chart, AbCellera Biologics ranks #587 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' EBITDA Margin % compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #587 out of 944 companies for EBITDA Margin %. This places AbCellera Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AbCellera Biologics and its competitors. AbCellera Biologics's current EBITDA Margin % is -535.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current EBITDA Margin % is -535.48%. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current EBITDA Margin % is -535.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
EBITDA Margin %: -535.48%
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
